Tavolixizumab (MEDI 0562, Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research[1].
Molecular Weight:
(146.36 kDa)
Purity:
99.76
CAS Number:
[1635395-25-3]
Target:
TNF Receptor
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted